Daewoong Pharmaceutical has entered the digital therapeutics business for patients with mild cognitive impairment, a condition known as the pre-stage of dementia.

On the 28th, Daewoong Pharmaceutical announced that it had signed a contract with digital healthcare company Imocog for the exclusive domestic sales and commercialization rights of “CogTera,” a digital therapeutic device for mild cognitive impairment, and “CogScreen,” a test that identifies the possibility of cognitive decline.

CogTera received approval from the Ministry of Food and Drug Safety in May last year as the first digital therapeutic device for mild cognitive impairment in Korea. Patients with a physician’s prescription can use CogTera for 12 weeks to receive cognitive training twice a day. Since its first prescription in October last year, it has been prescribed a cumulative 2,400 times as of the end of August this year. CogScreen is a test that, in about five minutes, screens for the possibility of cognitive decline and helps medical staff determine whether additional tests or treatment are needed. Testing is possible via a web link without installing a separate app.

In 2024, Korea entered a super-aged society, with the share of the population aged 65 and older exceeding 20%. Due to rapid aging, the number of people at risk of dementia is also increasing quickly. According to the Ministry of Health and Welfare, the prevalence of mild cognitive impairment among seniors aged 65 and older was 28.42% in 2023, up 6.17 percentage points from 22.25% in 2016. The number of dementia patients is also estimated to exceed 1 million this year.

Popular News